Compared with HRDetect, CHORD requires less preprocessing of the data, was trained on a pan-cancer cohort as opposed to a breast cancer cohort, and includes the ability to predict BRCA1 vs BRCA2 subtypes (Table 1). The gene discussed is BRCA2; the disease is breast carcinoma.